GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (NAS:VYGR) » Definitions » E10

Voyager Therapeutics (Voyager Therapeutics) E10 : $-1.38 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Voyager Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Voyager Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $1.190. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.38 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-03), Voyager Therapeutics's current stock price is $8.78. Voyager Therapeutics's E10 for the quarter that ended in Dec. 2023 was $-1.38. Voyager Therapeutics's Shiller PE Ratio of today is .


Voyager Therapeutics E10 Historical Data

The historical data trend for Voyager Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics E10 Chart

Voyager Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -1.38

Voyager Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -1.38

Competitive Comparison of Voyager Therapeutics's E10

For the Biotechnology subindustry, Voyager Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyager Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Shiller PE Ratio falls into.



Voyager Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Voyager Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.19/129.4194*129.4194
=1.190

Current CPI (Dec. 2023) = 129.4194.

Voyager Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201312 0.000 98.326 0.000
201406 0.000 100.560 0.000
201409 -0.300 100.428 -0.387
201412 -0.353 99.070 -0.461
201503 -1.075 99.621 -1.397
201506 -0.458 100.684 -0.589
201509 -0.269 100.392 -0.347
201512 -0.354 99.792 -0.459
201603 -0.290 100.470 -0.374
201606 -0.370 101.688 -0.471
201609 -0.350 101.861 -0.445
201612 -0.570 101.863 -0.724
201703 -0.650 102.862 -0.818
201706 -0.730 103.349 -0.914
201709 -0.890 104.136 -1.106
201712 -0.400 104.011 -0.498
201803 -0.630 105.290 -0.774
201806 -0.800 106.317 -0.974
201809 -0.630 106.507 -0.766
201812 -0.700 105.998 -0.855
201903 -0.810 107.251 -0.977
201906 0.290 108.070 0.347
201909 -0.410 108.329 -0.490
201912 -0.340 108.420 -0.406
202003 -0.660 108.902 -0.784
202006 -0.230 108.767 -0.274
202009 2.270 109.815 2.675
202012 -0.430 109.897 -0.506
202103 -0.580 111.754 -0.672
202106 -0.800 114.631 -0.903
202109 -0.670 115.734 -0.749
202112 0.150 117.630 0.165
202203 -0.560 121.301 -0.597
202206 -0.500 125.017 -0.518
202209 0.450 125.227 0.465
202212 -0.610 125.222 -0.630
202303 2.940 127.348 2.988
202306 -0.510 128.729 -0.513
202309 -0.590 129.860 -0.588
202312 1.190 129.419 1.190

Add all the adjusted EPS together and divide 10 will get our e10.


Voyager Therapeutics  (NAS:VYGR) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Voyager Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyager Therapeutics (Voyager Therapeutics) Business Description

Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.
Executives
Todd Alfred Carter officer: Chief Scientific Officer C/O VOYAGER THERAPEUTICS, INC., 64 SIDNEY STREET, CAMBRIDGE MA 02139
Robin Swartz officer: Chief Operating Officer C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Peter P. Pfreundschuh officer: Chief Financial Officer C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sandell Jacquelyn Fahey officer: Chief Legal Officer C/O VOYAGER THERAPEUTICS, INC., 64 SIDNEY STREET, CAMBRIDGE MA 02139
George A Scangos director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Alfred Sandrock director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Robert W. Hesslein officer: Senior VP & General Counsel C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Jude Onyia director C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Neurocrine Biosciences Inc 10 percent owner 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Third Rock Ventures Iii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Grace Colon director C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Glenn Pierce director
Michael J Higgins director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140